Needham upgrades Neurocrine on positive Crenessity survey

Needham analyst Ami Fadia upgraded Neurocrine (NBIX) to Buy from Hold with a $138 price target The firm cites its positive physician survey on Crenessity’s ramp in congenital adrenal hyperplasia for the upgrade. It increased sales estimates 8%-10% above consensus for 2026 and beyond and says the pullback in Neurocrine shares due to concerns on Ingrezza’s Q1 dynamics are overdone. The company can still hit its 2025 guidance and the impact from potential tariffs is likely to be minimal, the analyst tells investors in a research note.